Caliway's Fat Reduction Drug Candidate CBL-514 Completes U.S. FDA IND Submission for Phase 2 Clinical Study in Weight Management, Expanding Development Combined with GLP-1RA-Based Weight-Loss Therapies ...Middle East

Caliway has completed submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 2 clinical study of CBL-514 for weight management (CBL-0201WR Phase 2). The study will evaluate CBL-514 in combination with Zepbound® (Eli Lilly) in...

Hence then, the article about caliway s fat reduction drug candidate cbl 514 completes u s fda ind submission for phase 2 clinical study in weight management expanding development combined with glp 1ra based weight loss therapies was published today ( Thursday 25/12/2025 - 05:08 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Caliway's Fat Reduction Drug Candidate CBL-514 Completes U.S. FDA IND Submission for Phase 2 Clinical Study in Weight Management, Expanding Development Combined with GLP-1RA-Based Weight-Loss Therapies )

Also on site :

• Governor Hochul: Annual statewide donation drive is complete
• Tornado warning issued, and quickly cancelled, over Alhambra
• Skier dies in collision with tree at Colorado’s Aspen Mountain, resort officials confirm